Mireia Moreno, Jordi Gratacós, Victoria Navarro-Compán, Eugenio de Miguel, Pilar Font, Teresa Clavaguera, Luis Francisco Linares, Beatriz Joven, Xavier Juanola
OBJECTIVES: To study whether disease status at treatment initiation has changed after the issue of the ASAS classification criteria. METHODS: REGISPONSERBIO registers patients with axial spondyloarthritis (axSpA) on biological treatment since 2013. It includes patients starting biological treatment (incident) or already on biological therapies (prevalent). Patients in both groups were compared in terms of: age at disease onset and at treatment start, disease duration, gender, HLA-B27, body mass index (BMI), BASDAI, BASFI, C-reactive protein, ESR, metrological data, ASQoL, WAPAI, extra-articular manifestations, comorbidities, radiological study, type of biological treatment and concomitant treatments...
November 2018: Clinical and Experimental Rheumatology